Skip to main content
Equibles
CRVO logo

CRVO · CervoMed Inc.

Track CRVO — free

Use CRVO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRVO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.60 -0.04 (-1.52%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — cleared Aug 7, 2026

The latest filing no longer states the doubt (first flagged May 15, 2026).

View the 10-Q filed Aug 7, 2026
Market Cap
$39.76M
Shares
15.12M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.60 Open$2.64 Day$2.55–2.67 52W close$2.25–10.69 Avg vol 30d339K Short int963K · 6.4% float · 2.3d Short vol74% Last earningsJun 15, 2026 DataAug 2023–Aug 2026 Filing10-Q · Aug 7

Raw chart and full-history price indicators begin at the captured split on Aug 17, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −45%
below
Price vs 50-day avg −14%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 4%
near low
Momentum
relative strength
Very Weak
1-month return +1%
trailing
6-month return −43%
trailing
YTD return −67%
this year
Relative strength −56%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$3.0M over 90 days · 0% sells
Short interest Rising
6.37% of float · ▲ +15.6% MoM · 2.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Squeeze score 55
elevated · 0–100
Fundamentals
Weak
Revenue growth −59%
Y/Y
Gross margin 2%
expanding
EPS growth +5%
Y/Y
Free cash flow $-23.9M
Quant / Vol
risk profile
Very High
Volatility 114%
annualized · 1-yr
Max drawdown −79%
past year
ATR 7.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−45% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$3.0M over 90 days · 0% sells
Short interest Rising
6.37% of float · ▲ +15.6% MoM · 2.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 4% Range high $11
vs 200-day avg -45% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRVO
CervoMed Inc.
this stock
$39.76M -67.1% -58.9% — 6.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
37
% held
11.6%
Net QoQ
-22.5K sh
Top holder
Woodline Partners LP
Held Float
View
Held by Funds
Fund positions
10
View
Short & Settlement
Short Interest Rising
Shares short
962.6K
Days to cover
2.3d
Change
+130.2K sh
View
Short Volume
Short vol %
74%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
9.7K
Value
$25.7K
As of
Jul 27, 2026
View
Off-Exchange
Off-exchange %
63.7%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$3.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$4.0M
Net income (FY)
$-27.0M
EPS diluted
$3058336.50
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 30, 2026
This year
24
View
Exempt Offerings
Offering
$750.0K
Filed
May 27, 2020
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

Raw-price comparisons begin at the captured split on Aug 17, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
CRVO -0.8% +0.8% -42.7% +0.8% -67.1%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -1.2% -2.2% -56.2% -2.2% -79.9%
Key facts CIK 1053691 CUSIP 15713L109 13F (30d) 36 filings 35 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)